Aerie Pharmaceuticals, Inc (AERI) reported a Quarterly Revenue Growth (YOY) of 8.3%, and Revenue Per Share (TTM) $1.815
Aerie Pharmaceuticals, Inc (NASDAQ: AERI) opened the trading session on January 12, 2021, at $13.79, exposing a change of 4.1999% compared to the previous close at $13.81. During the trading session, the stock price jumped to $14.71 and declined to $13.79. Finally, the stock settled at $14.39. Though, bearing in mind a long-term vision, Aerie Pharmaceuticals, Inc reported a 52 Week Range in the range of $9.01-$25.23.
Aerie Pharmaceuticals, Inc's shares outstanding currently cost $46.81M, in addition to a float of $45.82M. AERI operates in the Healthcare sector of the Drug Manufacturers-Specialty & Generic industry and has a market capitalization of $673.66M (as of January 12, 2021). It's worth mentioning that Aerie Pharmaceuticals, Inc's 50-day Moving Average settled at $13.17, while such index as 200-day Moving Average is presently $12.25.
To measure the company's efficiency, let's take a look at Aerie Pharmaceuticals, Inc's conglomerate performance. At the moment, AERI has 380 full-time employees. Aerie Pharmaceuticals, Inc has generated $183,915.789 per worker During the last fiscal year. At the same time, AERI's income per employee was $-525,213.158. And now, let's take a look at the company's income report. Aerie Pharmaceuticals, Inc's Net Income for the last fiscal year was $-199,581,000, while such index as Income Before Taxes was at the level of $-199,671,000. AERI's Operating Income was at the mark of $-187,492,000.
Aerie Pharmaceuticals, Inc (AERI) Earnings & Revenue
Talking about the Profitability, AERI reached a Profit Margin of -231.05% and an Operating Margin (TTM) of -204.59%. However, when we touch the questions of management effectiveness, Aerie Pharmaceuticals, Inc generated a Return on Equity (TTM) of -142.61% and a Return on Assets (TTM) of -25.13%. A bit more income statements might bring clarity to our overview. According to the results of the latest quarter ended September 30, 2020, Aerie Pharmaceuticals, Inc generated Revenue (TTM) of $83.11M, reporting a Quarterly Revenue Growth of 8.3%. As for the Revenue Per Share (TTM), this indicator was at the mark of $1.815. The company's Gross Profit (TTM) was $42.29M, while according to the EBITDA report, it was estimated at $-199,219,008.
Aerie Pharmaceuticals, Inc (NASDAQ: AERI) Owners & Shares
Finally, let's take a look at the share statistics. As mentioned above, AERI's shares outstanding now amounts to $46.81M, where Shares Short was $5.64M versus the prior month amounted to $5.62M. (Short % of Float was 16.58%). And now, let's overview which kind of investors works with Aerie Pharmaceuticals, Inc's stocks. AERI's current ownership accounts for 109.26% institutional investors, while 2.105% of shares belong to the insiders. Also worth mentioning some indicators affecting dividends & splits. Thus, AERI's Forward Annual Dividend Rate is currently at the mark of 0, whereas the Dividend Yield is 0%, and a Dividend Payout Ratio is 0% (Dividend Date: December 31, 1969). The company's Dividend Per Share index thereby is $None.
AERI Trading Performance
It's time to observe the current performance indicators for Aerie Pharmaceuticals, Inc. AERI's price/earnings to growth ratio during the last reported quarter was 0%. The company's PE Ratio stands at None%, while AERI's Beta score is 0.7889. Also worth noting that Aerie Pharmaceuticals, Inc's Diluted EPS (Earnings per Share) trailing twelve months is at the mark of -4.193. Other valuable indicators are Price To Sales Ratio (TTM), which is currently recorded at 7.6159, as well as Price To Book Ratio, which amounts to 10.7656.
Aerie Pharmaceuticals, Inc Analysis & Estimates
Within the previous 9-day period, Aerie Pharmaceuticals, Inc's Average True Range (ATR) was 0.7179, while the stock's Stochastic SlowD moving average was 75.2511%, and the SlowK moving average volumed at 75.2511%.